ResultsIQ

ResultsIQ › Latest results › Yatharth Hospital & Trauma Care Services Limited

Yatharth Hospital & Trauma Care Services Limited Q4 FY25 results deck summary

NSE: YATHARTH · BSE: 543950

Results deck of 26 May 2025, summarised by AI from the filing.

Noida Extension and Jhansi-Orchha hospitals grew 50% and 68% YoY, contributing 37% and 7% of FY25 revenue.

Key takeaways

  1. Growth driver Noida Extension and Jhansi-Orchha hospitals grew 50% and 68% YoY, contributing 37% and 7% of FY25 revenue.

Original filing on BSE

Yatharth Hospital & Trauma Care Services Limited Q1 FY27 results

As filed: Revenue ₹393 cr (+52% year on year), EBITDA ₹91.7 cr (+41% year on year), PAT ₹45.4 cr (+8% year on year), EBITDA margin 23.4% (−184 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹342 cr (+47% year on year), EBITDA ₹79.9 cr (+38% year on year), PAT ₹44.7 cr (+15% year on year), EBITDA margin 23.4% (−160 bps). Score 69 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was below it. EBITDA margin fell 160 bps year on year. Tax rate 14%. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue rose ₹110 cr on a year ago, more than the ₹54.0 cr it added the year before. Share price after the results: −0.6% in 30 days (Nifty 500: +2.1%).
  • Q3 FY26: Revenue ₹320 cr (+46% year on year), EBITDA ₹74.3 cr (+35% year on year), PAT ₹43.1 cr (+44% year on year), EBITDA margin 23.2% (−195 bps). Score 88 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was above it. EBITDA margin fell 195 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +3.6% in 29 days (Nifty 500: −4.5%).
  • Q2 FY26: Revenue ₹279 cr (+28% year on year), EBITDA ₹65.0 cr (+18% year on year), PAT ₹41.0 cr (+32% year on year), EBITDA margin 23.3% (−193 bps). Score 64 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was above it. EBITDA margin fell 193 bps year on year. Revenue rose ₹61.0 cr on a year ago, more than the ₹47.0 cr it added the year before. Share price after the results: −5.3% in 29 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹258 cr (+22% year on year), EBITDA ₹65.0 cr (+23% year on year), PAT ₹42.0 cr (+40% year on year), EBITDA margin 25.2% (+19 bps). Score 57 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was in line with it; profit growth was above it. EBITDA margin rose 19 bps year on year. Revenue rose ₹46.0 cr on a year ago, against ₹57.0 cr the year before. Share price after the results: +18.1% in 30 days (Nifty 500: −0.2%).
  • Q4 FY25: Revenue ₹232 cr (+30% year on year), EBITDA ₹58.0 cr (+26% year on year), PAT ₹39.0 cr (+3% year on year), EBITDA margin 25.0% (−84 bps). Score 61 of 100, In line with trend. EBITDA margin fell 84 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +0.7% in 30 days (Nifty 500: +2.3%).
  • Q3 FY25: Revenue ₹219 cr (+31% year on year), EBITDA ₹55.0 cr (+17% year on year), PAT ₹30.0 cr (+3% year on year), EBITDA margin 25.1% (−303 bps). Score 55 of 100, In line with trend. EBITDA margin fell 303 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 3% from last quarter.
  • Q2 FY25: Revenue ₹218 cr (+27% year on year), EBITDA ₹55.0 cr (+20% year on year), PAT ₹31.0 cr (+11% year on year), EBITDA margin 25.2% (−167 bps). Score 59 of 100, In line with trend. EBITDA margin fell 167 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Yatharth Hospital & Trauma Care Services Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.